Early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X tremor-ataxia syndrome (or FXTAS).
$4.50 - $6.50
August 26, 2022
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277